Viz.ai and ALCMI Partner to Improve Lung Cancer Outcomes
09/04/24, 4:10 PM
Location
Industry
health care
artificial intelligence
Type
partnership
Viz.ai has announced a partnership with ALCMI to collaborate on improving lung cancer outcomes, focusing on early detection and precision medicine optimization. The partnership aims to define the future of lung cancer research and treatment, with the ultimate goal of improving patient outcomes.
Company Info
Location
san francisco, california, united states
Additional Info
Viz.ai, located in San Francisco, Tel Aviv, Portugal and Amsterdam, pioneered the use of AI algorithms and machine learning to increase the speed of diagnosis and care for a variety of acute and emergent diseases across hospitals and health systems. The Viz Platform is a transformative, intelligent care coordination solution that unifies synchronized care collaboration, high fidelity mobile image viewing, automated workflows and improved visibility at decision-making moments. Viz.ai’s comprehensive neurovascular and vascular AI platform is clinically proven to save time and improve patient outcomes and access to care and is used in more than 1,000 hospitals in the US and EMEA. Viz.ai’s life science portfolio expands the power of the AI-powered Viz Platform to pharmaceutical and medical device companies who are leaning into digital transformation to bring life-saving therapies to market more efficiently. The company was named to the Forbes 2021 Next Billion-Dollar Startups list of the 25 fastest-growing venture-backed startups and has been on the Forbes AI 50 list for three consecutive years. For more information visit viz.ai.